BLA 761311. Not in Drugs@FDA, which lists approved applications only; FDA's complete response letters name it.
As of Nov 21, 2026, BLA 761311 (Relabotulinumtoxin A) is not in Drugs@FDA, which lists approved applications; FDA has published 2 complete response letters for it.
| Jun 29, 2026 | Relabotulinumtoxin AFacility Inspections, Product Quality | Unapproved |
| Sep 29, 2023 | BLA 761311Product Quality | Unapproved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters